Enzymatic Wound Debridement Market Size (2024 - 2029)

The enzymatic wound debridement market is expected to experience growth over the forecast period, driven by an increase in chronic diseases such as diabetes and cancer, which elevate the risk of chronic wounds. The market's expansion is further supported by the recovery from the COVID-19 pandemic, characterized by a rise in wound care product sales and new product launches. Technological advancements and strategic activities like mergers and acquisitions are also contributing to the market's growth. However, the market's expansion may face challenges due to stringent regulatory policies.

Market Size of Enzymatic Wound Debridement Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Enzymatic Wound Debridement Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 5.30 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Enzymatic Wound Debridement Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Enzymatic Wound Debridement Market Analysis

The enzymatic wound debridement market is projected to grow with a CAGR of nearly 5.3% over the forecast period.

The COVID-19 outbreak impacted the enzymatic wound debridement market and the overall healthcare sector during the initial phases, as hospitals and healthcare services were reduced due to social distancing measures taken by governments worldwide. According to an article in September 2021 by the American Journal of Managed Care, during COVID-19, a large number of patients with chronic wounds delayed preventative and urgent wound care due to the lockdown. Such delays profoundly impacted the market's growth. During the pandemic, wound care was prioritized to avoid significant wound complications by reducing hospitalization and surgery. The reduction in the available wound care management services during the COVID-19 pandemic impacted the market growth. However, the sector has been recovering well since restrictions were lifted. An increase in wound care product sales, new product launches, and increasing demand for a faster cure for chronic wounds leading the market recovery over the last two years.

The major factors attributing to the growth of the market include the increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases. For instance, according to the IDF Diabetes Atlas 10th edition 2021, an estimated 537 million adults live with diabetes worldwide. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. The risk of foot ulcers increases with uncontrolled diabetes. The rising cases of diabetic people indicate a higher risk for the rising number of chronic wounds such as diabetic foot ulcers, which is augmenting the growth of the market studied. Moreover, as per Mission Regional Medical Center 2022 update, it is estimated that 6.7 million people currently live with chronic wounds, and that number is expected to grow by more than 2% for the next decade. Chronic wounds cost the healthcare system more than USD 50 billion each year. In the United States, more than 29 million people (9.5% of the population) have diabetes, and nearly two million of those people are likely to develop a diabetic foot ulcer or another non-healing wound each year. Hence considering the advantages of enzymatic wound debridement, the market is anticipated to witness growth over the forecast period.

Furthermore, product launches, mergers, and acquisitions in the field of enzymatic wound debridement are anticipated to boost market growth over the forecast period. For instance, in August 2022, 3M Health Care's Medical Solutions Division introduced a new 3M Veraflo Cleanse Choice Complete Dressing Kit and a software upgrade for the 3M V.A.C. These new products assisted the doctors employing Veraflo Therapy (negative pressure wound therapy with instillation) in simplifying care delivery processes and making wound dressing changes easier, faster, and less stressful for their patients when compared to previous Veraflo Therapy dressings.

Hence, due to the increase in the incidence of chronic diseases like diabetes, the rise in the number of accidents, and technological advancements in enzymatic wound debridement products, the enzymatic wound debridement market is anticipated to witness growth over the forecast period. However, stringent regulatory policies are likely to restrain the market growth over the forecast period.

Enzymatic Wound Debridement Industry Segmentation

As per the scope of the report, debridement is the procedure in which infected tissue is removed from the wound until the healthy tissue is exposed. Enzymatic debridement is the process of using exogenous enzymes to the surface of the wound so the degradation of necrotic tissue can occur without any negative effects on viable, granulation tissue. The Enzymatic Wound Debridement Market is Segmented by Type (Chronic Wounds, Acute Wounds), Product (Collagenase Product, Papain Product, and Others), End-User (Hospitals, Homecare, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Type
Chronic Wounds
Acute Wounds
By Product
Collagenase Product
Papain Product
Others
By End-User
Hospitals
Homecare
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Enzymatic Wound Debridement Market Size Summary

The enzymatic wound debridement market is poised for growth, driven by an increasing incidence of chronic diseases such as diabetes and cancer, which elevate the risk of chronic wounds like diabetic foot ulcers. The market experienced initial setbacks due to the COVID-19 pandemic, which led to delays in wound care as healthcare services were curtailed. However, the sector has shown resilience and is recovering, supported by a rise in product sales, new product launches, and a growing demand for efficient chronic wound management solutions. Technological advancements, such as the introduction of innovative products like the 3M Veraflo Cleanse Choice Complete Dressing Kit, are further propelling market expansion. Despite the positive outlook, the market faces challenges from stringent regulatory policies that could potentially hinder growth.

North America is expected to be a significant growth region for the enzymatic wound debridement market, attributed to the high prevalence of chronic diseases and accidents, coupled with a robust healthcare infrastructure. The presence of key industry players and ongoing product innovations, such as MediWound's EscharEx, are likely to enhance market dynamics. The market is moderately competitive, with major companies like B. Braun Melsungen AG, ConvaTec Inc., and Smith & Nephew playing pivotal roles. As the demand for effective wound care solutions continues to rise, driven by factors such as the increasing number of chronic wounds and accidents, the enzymatic wound debridement market is anticipated to witness sustained growth over the forecast period.

Explore More

Enzymatic Wound Debridement Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Incidence of Chronic Wounds

      2. 1.2.2 Increasing Number of Accidents

      3. 1.2.3 Increasing Technologically Advanced Products

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent regulatory policies

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - in USD Millions)

    1. 2.1 By Type

      1. 2.1.1 Chronic Wounds

      2. 2.1.2 Acute Wounds

    2. 2.2 By Product

      1. 2.2.1 Collagenase Product

      2. 2.2.2 Papain Product

      3. 2.2.3 Others

    3. 2.3 By End-User

      1. 2.3.1 Hospitals

      2. 2.3.2 Homecare

      3. 2.3.3 Others

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Enzymatic Wound Debridement Market Size FAQs

The Enzymatic Wound Debridement Market is projected to register a CAGR of 5.30% during the forecast period (2024-2029)

B. Braun Melsungen AG, ConvaTec Inc., Smith & Nephew, Integra LifeSciences Corporation and Mölnlycke Health Care AB are the major companies operating in the Enzymatic Wound Debridement Market.

Enzymatic Wound Debridement Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)